Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK plus NSCLC in the ALTA-1L and J-ALTA studies

JOURNAL OF CLINICAL ONCOLOGY(2023)

Cited 0|Views12
No score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined